Post-effective amendment to a registration statement that is not immediately effective upon filing

Stock Based Compensation - Additional Information (Details)

v3.22.1
Stock Based Compensation - Additional Information (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
May 24, 2021
$ / shares
shares
May 23, 2021
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Equity Incentive Plan [Line Items]        
Expected dividend yield     0.00%  
Weighted average grant date fair value | $ / shares     $ 16.57 $ 13.80
Unrecognized compensation     $ 31,100  
Weighted-average period     1 year 25 days  
Stock-based compensation expense allocated     $ 7,785 $ 730
Merger agreement        
Equity Incentive Plan [Line Items]        
Exchange Ratio 3.16      
Merger agreement | Stockholders of NeuroRx        
Equity Incentive Plan [Line Items]        
Exchange Ratio 3.16 4.96    
Substitute Options        
Equity Incentive Plan [Line Items]        
Share-based Payment Arrangement, Plan Modification, Incremental Cost     25,900  
General and Administrative Expense [Member]        
Equity Incentive Plan [Line Items]        
Stock-based compensation expense allocated     6,500 332
Research and Development Expense [Member]        
Equity Incentive Plan [Line Items]        
Stock-based compensation expense allocated     $ 1,285 $ 398
2016 Omnibus Inventive Plan [Member]        
Equity Incentive Plan [Line Items]        
Share-based compensation arrangement by share-based payment award, number of shares authorized | shares     3,472,000  
Options to purchase shares of common Stock | shares 2,895,423   2,400,315 2,414,303
Exercise price | $ / shares $ 5.10   $ 6.28 $ 2.17